ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

被引：11

作者：

Holle, J. U. ^{[1
]}

Gross, W. L.

机构：

[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, D-23538 Lubeck, Germany

来源：

JOURNAL OF AUTOIMMUNITY | 2009年 / 32卷 / 3-4期

关键词：

ANCA-associated vasculitis; Wegener's granulomatosis; Evidence-based therapy; EULAR recommendations; CHURG-STRAUSS-SYNDROME; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; REFRACTORY WEGENERS-GRANULOMATOSIS; ANTIBODY-ASSOCIATED VASCULITIS; TNF-ALPHA BLOCKADE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TERM-FOLLOW-UP; RANDOMIZED-TRIAL; MYCOPHENOLATE-MOFETIL; POLYARTERITIS-NODOSA;

D O I：

10.1016/j.jaut.2009.02.019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：163 / 171

页数：9

共 117 条

[1] Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis [J].

Adu, D ;

Pall, A ;

Luqmani, RA ;

Richards, NT ;

Howie, AJ ;

Emery, P ;

Michael, J ;

Savage, COS ;

Bacon, PA .

QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1997, 90 (06) :401-409

[2] Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-α blockade [J].

Arbach, O ;

Gross, WL ;

Gause, A .

IMMUNOBIOLOGY, 2002, 206 (05) :496-501

[3] Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations [J].

Aries, P. M. ;

Hellmich, B. ;

Voswinkel, J. ;

Both, M. ;

Noelle, B. ;

Holl-Ulrich, K. ;

Lamprecht, P. ;

Gross, W. L. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :853-858

[4] The spectrum of Wegener's granulomatosis and disease relapse [J].

Bacon, PA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (04) :330-332

[5] Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides:: an open pilot study on 10 patients [J].

Bartolucci, P ;

Ramanoelina, J ;

Cohen, P ;

Mahr, A ;

Godmer, P ;

Le Hello, C ;

Guillevin, L .

RHEUMATOLOGY, 2002, 41 (10) :1126-1132

[6] Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: Systematic review [J].

Birck, R ;

Schmitt, WH ;

Kaelsch, IA ;

van der Woude, FJ .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (01) :15-23

[7] 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis:: A six-month open-label trial to evaluate safety and efficacy [J].

Birck, R ;

Warnatz, K ;

Lorenz, HM ;

Choi, M ;

Haubitz, M ;

Grünke, M ;

Peter, HH ;

Kalden, JR ;

Göbel, U ;

Drexler, JM ;

Hotta, O ;

Nowack, R ;

Van der Woude, FJ .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (02) :440-447

[8] Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis [J].

Booth, A ;

Harper, L ;

Hammad, T ;

Bacon, P ;

Griffith, M ;

Levy, J ;

Savage, C ;

Pusey, C ;

Jayne, D .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :717-721

[9] Safety and efficacy of TNFα blockade in relapsing vasculitis [J].

Booth, AD ;

Jefferson, HJ ;

Ayliffe, W ;

Andrews, PA ;

Jayne, DR .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (06) :559-559

[10]

Brihaye B, 2007, CLIN EXP RHEUMATOL, V25, pS23

← 1 2 3 4 5 6 7 8 9 10 →